Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 8 |
| 1.1 List of Tables | 6 | 2 |
| 1.2 List of Figures | 8 | 3 |
| Global Blood Disorders Market: Introduction | 11 | 2 |
| 2.1 GBI Research Report Guidance | 12 | 1 |
| 3 Global Blood Disorders Market: Market Overview | 13 | 14 |
| 3.1 Introduction | 13 | 1 |
| 3.2 Revenue Forecasts for the Global Blood Disorders Market | 14 | 1 |
| 3.2.1 Sales Value | 14 | 1 |
| 3.2.2 Sales Volume | 15 | 1 |
| Annual Cost of Therapy | 16 | 1 |
| 3.2.4 Treatment Usage Patterns | 17 | 2 |
| 3.2.4.1 Diseased Population | 19 | 1 |
| 3.2.4.2 Treatment Seeking Population | 19 | 1 |
| 3.2.4.3 Diagnosed Population | 20 | 1 |
| 3.2.4.4 Prescription Population | 21 | 1 |
| Generics Share in the Global Blood Disorders Market | 22 | 2 |
| 3.3 Blood Disorders Market Drivers | 24 | 1 |
| 3.3.1 Steady Increase in the Prevalence Population, Particularly in Anemia, in the Top Five Countries in Europe | 24 | 1 |
| 3.3.2 Rapid Uptake of Biologics Products due to Better Efficacy and Safety in Diseases Such as Anemia, Hemophilia and Neutropenia | 24 | 1 |
| 3.3.3 Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable | 24 | 1 |
| 3.3.4 Increase in Conditions Such as Cancer and Cardiovascular Events will Increase the Prevalence of Blood Disorders | 25 | 1 |
| 3.4 Blood Disorders Market Restraints | 25 | 1 |
| 3.4.1 Low Diagnosis Rate as the Contemporary Diagnostic Tools are Unable to Diagnose the Severe Forms of Blood Disorders | 25 | 1 |
| 3.4.2 Patent Expiries of Major Blockbusters Including Plavix, Lovenox, Aranesp, Neulasta, Procrit and Others Pose a Threat to Leading Players in the Market | 25 | 1 |
| 3.4.3 The Clearance of the Regulatory Pathway in the US Will Open up the World s Largest Pharmaceutical Market to Biosimilar Players | 26 | 1 |
| 3.4.4 Sluggish Growth in the Annual Cost of Therapy for Blood Disorders is Expected To Drive Down the Growth Rate | 26 | 1 |
| 4 Global Blood Disorders Market: Therapeutic Landscape | 27 | 61 |
| 4.1 Anemia Market | 27 | 1 |
| 4.1.1 Introduction | 27 | 1 |
| 4.1.2 Sales Value | 27 | 1 |
| 4.1.3 Sales Volume | 28 | 2 |
| 4.1.4 Annual Cost of Therapy | 30 | 1 |
| 4.1.5 Treatment Usage Patterns | 31 | 1 |
| 4.1.5.1 Diseased Population | 32 | 2 |
| 4.1.5.2 Treatment Seeking Population | 34 | 1 |
| 4.1.5.3 Diagnosed Population | 35 | 1 |
| 4.1.5.4 Prescription Population | 36 | 1 |
| 4.1.6 Geographical Segmentation | 36 | 4 |
| 4.1.7 Generics Share of the Global Anemia Market | 40 | 2 |
| 4.2 Thrombosis Market | 42 | 1 |
| 4.2.1 Introduction | 42 | 1 |
| 4.2.2 Sales Value | 42 | 2 |
| 4.2.3 Sales Volume | 44 | 1 |
| Annual Cost of Therapy | 45 | 2 |
| 4.2.5 Treatment Usage Patterns | 47 | 1 |
| 4.2.5.1 Diseased Population | 48 | 1 |
| 4.2.5.2 Treatment Seeking Population | 49 | 1 |
| 4.2.5.3 Diagnosed Population | 50 | 1 |
| 4.2.5.4 Prescription Population | 51 | 1 |
| 4.2.6 Geographical Segmentation | 52 | 3 |
| 4.2.7 Generics Share of the Global Thrombosis Market | 55 | 1 |
| 4.3 Hemophilia Market | 56 | 1 |
| 4.3.1 Introduction | 56 | 2 |
| 4.3.2 Sales Value | 58 | 1 |
| 4.3.3 Sales Volume | 59 | 1 |
| 4.3.4 Annual Cost of Therapy | 60 | 2 |
| 4.3.5 Treatment Usage Patterns | 62 | 1 |
| 4.3.5.1 Diseased Population | 63 | 1 |
| 4.3.5.2 Treatment Seeking Population | 63 | 2 |
| 4.3.5.3 Diagnosed Population | 65 | 1 |
| 4.3.5.4 Prescription Population | 66 | 1 |
| 4.3.6 Geographical Segmentation | 67 | 3 |
| 4.3.7 Generics Share in the Global Hemophilia Market | 70 | 2 |
| 4.4 Neutropenia Market | 72 | 1 |
| 4.4.1 Introduction | 72 | 1 |
| 4.4.2 Sales Value | 73 | 1 |
| 4.4.3 Sales Volume | 74 | 1 |
| Annual Cost of Therapy | 75 | 2 |
| 4.4.5 Treatment Usage Patterns | 77 | 1 |
| 4.4.5.1 Diseased Population | 78 | 1 |
| 4.4.5.2 Treatment Seeking Population | 79 | 1 |
| 4.4.5.3 Diagnosed Population | 80 | 1 |
| 4.4.5.4 Prescription Population | 81 | 1 |
| 4.4.6 Geographical Segmentation | 82 | 3 |
| 4.4.7 Generics Share in the Global Neutropenia Market | 85 | 3 |
| 5 Global Blood Disorders Market: Geographical Landscape | 88 | 27 |
| 5.1 Geographical Break-up | 88 | 3 |
| 5.2 The US | 91 | 1 |
| 5.2.1 Sales Value | 91 | 1 |
| 5.2.2 Sales Volume | 92 | 1 |
| 5.2.3 Annual Cost of Therapy | 93 | 1 |
| 5.2.4 Treatment Usage Patterns | 94 | 1 |
| 5.2.4.1 Diseased Population | 95 | 1 |
| 5.2.4.2 Treatment Seeking Population | 96 | 1 |
| 5.2.4.3 Diagnosed Population | 97 | 1 |
| 5.2.4.4 Prescription Population | 97 | 1 |
| 5.3 Top Five Countries in Europe | 98 | 1 |
| 5.3.1 Sales Value | 98 | 2 |
| 5.3.2 Sales Volume | 100 | 1 |
| 5.3.3 Annual Cost of Therapy | 101 | 2 |
| 5.3.4 Treatment Usage Patterns | 103 | 1 |
| 5.3.4.1 Diseased Population | 104 | 1 |
| 5.3.4.2 Treatment Seeking Population | 105 | 1 |
| 5.3.4.3 Diagnosed Population | 106 | 1 |
| 5.3.4.4 Prescription Population | 107 | 1 |
| 5.4 Japan | 107 | 1 |
| 5.4.1 Sales Value | 107 | 1 |
| 5.4.2 Sales Volume | 108 | 2 |
| 5.4.3 Annual Cost of Therapy | 110 | 1 |
| 5.4.4 Treatment Usage Patterns | 111 | 1 |
| 5.4.4.1 Diseased Population | 112 | 1 |
| 5.4.4.2 Treatment Seeking Population | 113 | 1 |
| 5.4.4.3 Diagnosed Population | 113 | 1 |
| 5.4.4.4 Prescription Population | 114 | 1 |
| 6 Global Blood Disorders Market: Pipeline Analysis | 115 | 8 |
| 6.1 Introduction | 115 | 1 |
| 6.1.1 Research and Development Pipeline Anemia | 116 | 1 |
| 6.1.2 Research and Development Pipeline Thrombosis | 117 | 1 |
| 6.1.3 Research and Development Pipeline Hemophilia | 117 | 1 |
| 6.1.4 Research and Development Pipeline Neutropenia | 118 | 1 |
| Profiles of Key Late-Stage Drugs in the Blood Disorders Market | 119 | 1 |
| 6.2.1 Xarelto | 119 | 1 |
| 6.2.1.1 Introduction | 119 | 1 |
| 6.2.1.2 Mechanism of Action | 119 | 1 |
| 6.2.1.3 Clinical Trial Management | 119 | 1 |
| 6.2.2 AVE-5026 | 120 | 1 |
| 6.2.2.1 Introduction | 120 | 1 |
| 6.2.2.2 Mechanism of Action | 120 | 1 |
| 6.2.2.3 Clinical Trial Management | 120 | 1 |
| 6.2.3 Apixaban | 121 | 1 |
| 6.2.3.1 Introduction | 121 | 1 |
| 6.2.3.2 Mechanism of Action | 121 | 1 |
| 6.2.3.3 Clinical Trial Management | 121 | 1 |
| 6.2.4 Hematide | 121 | 1 |
| 6.2.4.1 Introduction | 121 | 1 |
| 6.2.4.2 Mechanism of Action | 121 | 1 |
| 6.2.4.3 Clinical Trial Management | 121 | 1 |
| 6.2.5 MAXY G34 | 122 | 1 |
| 6.2.5.1 Introduction | 122 | 1 |
| 6.2.5.2 Mechanism of Action | 122 | 1 |
| 6.2.5.3 Clinical Trial Management | 122 | 1 |
| 7 Global Blood Disorders Market: Competitive Landscape | 123 | 6 |
| 7.1 Market Share Analysis: Blood Disorders | 123 | 1 |
| 7.2 Competitive Profiling | 124 | 1 |
| 7.2.1 Amgen | 124 | 1 |
| 7.2.1.1 Product Portfolio | 125 | 1 |
| 7.2.2 Sanofi-Aventis | 126 | 1 |
| 7.2.2.1 Product Portfolio | 126 | 1 |
| 7.2.3 Bristol-Myers Squibb | 126 | 1 |
| 7.2.3.1 Product Portfolio | 127 | 1 |
| 7.2.4 Centocor Ortho Biotech Inc. | 127 | 1 |
| 7.2.4.1 Product Portfolio | 127 | 1 |
| 7.2.5 Baxter | 128 | 1 |
| 7.2.5.1 Product Portfolio | 128 | 1 |
| 8 Global Blood Disorders Market: Strategic Consolidations | 129 | 11 |
| 8.1 Overview | 129 | 1 |
| 8.1.1 GlaxoSmithKline Acquired JCR Pharmaceuticals Co Ltd. in December 2009 | 130 | 1 |
| 8.1.2 Biovitrum AB Acquired Swedish Orphan International AB in November 2009 | 131 | 1 |
| 8.1.3 LFB Biotechnologies Acquired GTC Biotherapeutics Inc in November 2009 | 131 | 1 |
| 8.1.4 Watson Pharmaceuticals Acquired Arrow Group in June 2009 | 131 | 1 |
| 8.1.5 Sanofi-Aventis SA Acquired Medley Pharmaceuticals in April 2009 | 131 | 1 |
| 8.1.6 Merck &Co. Acquired Insmed Corporation in February 2009 | 132 | 1 |
| 8.1.7 Pfizer Acquired Wyeth in January 2009 | 132 | 1 |
| 8.2 R&D Licensing Agreements | 132 | 1 |
| 8.2.1 Deals by Indication | 132 | 1 |
| 8.2.2 Deals by Phase | 133 | 1 |
| 8.2.3 Deals by Geography | 133 | 1 |
| 8.2.4 Deals by Licensing Type | 134 | 1 |
| 8.2.5 Deals by Value ($) | 135 | 1 |
| 8.2.6 Preclinical | 135 | 1 |
| 8.2.6.1 Evotec/Vifor Anemia Program | 135 | 1 |
| 8.2.6.2 Intravenous Recombinant Factor IX | 136 | 1 |
| 8.2.6.3 CB813 | 136 | 1 |
| 8.2.6.4 rhFVIIa Program | 136 | 1 |
| 8.2.7 Phase II | 136 | 1 |
| 8.2.7.1 Fostamatinib Disodium | 137 | 1 |
| 8.2.7.2 Intravenous Recombinant Factor IX | 137 | 1 |
| 8.2.7.3 Recombinant Porcine Factor VIII, B-domain Deleted | 137 | 1 |
| 8.2.7.4 FX06 | 138 | 1 |
| 8.2.7.5 Betrixaban | 138 | 1 |
| 8.2.8 Phase III | 138 | 1 |
| 8.2.8.1 MAXY-G34 | 138 | 1 |
| 8.2.9 Filed/Approved | 139 | 1 |
| 8.2.9.1 Sodium Ferric Gluconate Complex In Sucrose Injection | 139 | 1 |
| 8.2.9.2 Theragran-H | 139 | 1 |
| 8.2.9.3 KINLYTIC | 139 | 1 |
| 9 Global Blood Disorders Market: Appendix | 140 | 6 |
| 9.1 Market Definitions | 140 | 1 |
| 9.2 Abbreviations | 140 | 1 |
| 9.3 Research Methodology | 141 | 4 |
| 9.3.1 Coverage | 141 | 1 |
| 9.3.2 Secondary Research | 142 | 1 |
| 9.3.3 Primary Research | 142 | 1 |
| 9.3.4 Forecasts | 142 | 1 |
| 9.3.4.1 Epidemiology-based Forecasting | 142 | 2 |
| 9.3.5 Expert Panel Validation | 144 | 1 |
| 9.4 Contact Us | 145 | 1 |
| 9.5 Disclaimer | 145 | 1 |
| 9.6 Sources | 145 | 1 |